Drug news
FDA approves Gintuit (Organogenesis) for Mucogingival Conditions
The FDA on 9 March 2012 approved Gintuit from Organogenesis Inc., being the first cell-based product made from allogeneic human cells (from a donor unrelated to the patient) and bovine collagen. Gintuit is indicated for topical (non-submerged) application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults. With Gintuit, Organogenesis hopes to address the drawbacks of oral soft tissue procedures, precluding the need for patient-donated tissue grafts, eliminating pain and complications at the patient-tissue donor site, and regenerating aesthetically appealing tissue.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins